Replicel Life Sciences Inc
XTSX:RP

Watchlist Manager
Replicel Life Sciences Inc Logo
Replicel Life Sciences Inc
XTSX:RP
Watchlist
Price: 0.01 CAD Market Closed
Market Cap: 636.6k CAD
Have any thoughts about
Replicel Life Sciences Inc?
Write Note

Intrinsic Value

RP doesn't have a meaningful market cap.
RP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RP stock under the Base Case scenario is 0.04 CAD. Compared to the current market price of 0.01 CAD, Replicel Life Sciences Inc is Undervalued by 77%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RP Intrinsic Value
0.04 CAD
Undervaluation 77%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Replicel Life Sciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RP?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Replicel Life Sciences Inc

Provide an overview of the primary business activities
of Replicel Life Sciences Inc.

What unique competitive advantages
does Replicel Life Sciences Inc hold over its rivals?

What risks and challenges
does Replicel Life Sciences Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Replicel Life Sciences Inc.

Provide P/S
for Replicel Life Sciences Inc.

Provide P/E
for Replicel Life Sciences Inc.

Provide P/OCF
for Replicel Life Sciences Inc.

Provide P/FCFE
for Replicel Life Sciences Inc.

Provide P/B
for Replicel Life Sciences Inc.

Provide EV/S
for Replicel Life Sciences Inc.

Provide EV/GP
for Replicel Life Sciences Inc.

Provide EV/EBITDA
for Replicel Life Sciences Inc.

Provide EV/EBIT
for Replicel Life Sciences Inc.

Provide EV/OCF
for Replicel Life Sciences Inc.

Provide EV/FCFF
for Replicel Life Sciences Inc.

Provide EV/IC
for Replicel Life Sciences Inc.

Show me price targets
for Replicel Life Sciences Inc made by professional analysts.

What are the Revenue projections
for Replicel Life Sciences Inc?

How accurate were the past Revenue estimates
for Replicel Life Sciences Inc?

What are the Net Income projections
for Replicel Life Sciences Inc?

How accurate were the past Net Income estimates
for Replicel Life Sciences Inc?

What are the EPS projections
for Replicel Life Sciences Inc?

How accurate were the past EPS estimates
for Replicel Life Sciences Inc?

What are the EBIT projections
for Replicel Life Sciences Inc?

How accurate were the past EBIT estimates
for Replicel Life Sciences Inc?

Compare the revenue forecasts
for Replicel Life Sciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Replicel Life Sciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Replicel Life Sciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Replicel Life Sciences Inc compared to its peers.

Compare the P/E ratios
of Replicel Life Sciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Replicel Life Sciences Inc with its peers.

Analyze the financial leverage
of Replicel Life Sciences Inc compared to its main competitors.

Show all profitability ratios
for Replicel Life Sciences Inc.

Provide ROE
for Replicel Life Sciences Inc.

Provide ROA
for Replicel Life Sciences Inc.

Provide ROIC
for Replicel Life Sciences Inc.

Provide ROCE
for Replicel Life Sciences Inc.

Provide Gross Margin
for Replicel Life Sciences Inc.

Provide Operating Margin
for Replicel Life Sciences Inc.

Provide Net Margin
for Replicel Life Sciences Inc.

Provide FCF Margin
for Replicel Life Sciences Inc.

Show all solvency ratios
for Replicel Life Sciences Inc.

Provide D/E Ratio
for Replicel Life Sciences Inc.

Provide D/A Ratio
for Replicel Life Sciences Inc.

Provide Interest Coverage Ratio
for Replicel Life Sciences Inc.

Provide Altman Z-Score Ratio
for Replicel Life Sciences Inc.

Provide Quick Ratio
for Replicel Life Sciences Inc.

Provide Current Ratio
for Replicel Life Sciences Inc.

Provide Cash Ratio
for Replicel Life Sciences Inc.

What is the historical Revenue growth
over the last 5 years for Replicel Life Sciences Inc?

What is the historical Net Income growth
over the last 5 years for Replicel Life Sciences Inc?

What is the current Free Cash Flow
of Replicel Life Sciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Replicel Life Sciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Replicel Life Sciences Inc

Current Assets 196.7k
Cash & Short-Term Investments 32.5k
Receivables 103.8k
Other Current Assets 60.4k
Non-Current Assets 134.8k
PP&E 1.2k
Other Non-Current Assets 133.6k
Current Liabilities 1.5m
Accounts Payable 391.4k
Other Current Liabilities 1.1m
Non-Current Liabilities 5.5m
Long-Term Debt 41k
Other Non-Current Liabilities 5.4m
Efficiency

Earnings Waterfall
Replicel Life Sciences Inc

Revenue
353.7k CAD
Operating Expenses
-1.7m CAD
Operating Income
-1.4m CAD
Other Expenses
1.3m CAD
Net Income
-69.3k CAD

Free Cash Flow Analysis
Replicel Life Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RP Profitability Score
Profitability Due Diligence

Replicel Life Sciences Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional 3-Year Average ROE
Exceptional ROIC
Negative 1-Year Revenue Growth
49/100
Profitability
Score

Replicel Life Sciences Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

RP Solvency Score
Solvency Due Diligence

Replicel Life Sciences Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Short-Term Solvency
Long-Term Solvency
34/100
Solvency
Score

Replicel Life Sciences Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RP Price Targets Summary
Replicel Life Sciences Inc

There are no price targets for RP.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RP?

Click here to dive deeper.

Dividends

Replicel Life Sciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Replicel Life Sciences Inc Logo
Replicel Life Sciences Inc

Country

Canada

Industry

Life Sciences Tools & Services

Market Cap

614.3k CAD

Dividend Yield

0%

Description

RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.

Contact

BRITISH COLUMBIA
Vancouver
570 Granville St Suite 900
+16042488693.0
www.replicel.com

IPO

2012-09-29

Employees

1

Officers

President, CEO & Director
Mr. Andrew Schutte
Co-Founder & Chief Scientific Officer
Dr. Kevin John McElwee Ph.D.
Chief Legal Officer, Corporate Secretary & COO
Mr. Ben Austring
Chief Financial Officer
Mr. David Kwok CPA

See Also

Discover More
What is the Intrinsic Value of one RP stock?

The intrinsic value of one RP stock under the Base Case scenario is 0.04 CAD.

Is RP stock undervalued or overvalued?

Compared to the current market price of 0.01 CAD, Replicel Life Sciences Inc is Undervalued by 77%.

Back to Top